Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CWADI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AZD9592
|
|||||
| Synonyms |
AZD 9592; AZD-9592; AZD9592; Tilatamig samrotecan
Click to Show/Hide
|
|||||
| Organization |
AstraZeneca PLC
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 4 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Tilatamig
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
AZ0132
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
samrotecan
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Patients with metastatic non-small cell lung cancer (mNSCLC) with EGFRm (sensitizing L858R mutation or exon 19 deletions) or EGFR wild-type, or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05647122 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1, multicenter, open-label, first-in-human, dose escalation and expansion study of AZD9592 as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors. | ||||
References